PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), a pioneering force in the development of innovative cancer immunotherapies, has announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting. Set to unfold in San Diego, California, from April 5-10, 2024, this event will serve as a platform for Carisma to present preclinical data and insights into its groundbreaking Engineered Microenvironment Converters (EM-C) platform.
A key highlight of Carisma’s involvement is the poster presentation titled “Macrophages Expressing Synthetic Cytokine Receptors Reverse IL10-Mediated Immunosuppression within Solid Tumors and Promote Adaptive Immunity.” Scheduled for Tuesday, April 9, 2024, this session will offer a deep dive into how Carisma’s proprietary technology is paving new pathways in the fight against cancer by leveraging macrophages—a type of white blood cell instrumental in the immune response—to counteract the immunosuppressive environments typically found within solid tumors.
Moreover, Michael Klichinsky, PharmD, PhD, Co-Founder, and Chief Scientific Officer at Carisma, is slated to shed further light on these advancements during a Major Symposium session. His presentation, “Engineering Macrophages for Cancer Immunotherapy: CARs and Beyond,” will explore the novel approaches and engineering strategies being employed to enhance the efficacy of macrophages in cancer treatment. The session is part of a broader discussion on “Engineering Strategies Based on NK, gd T Cells and Their Receptors, and Macrophages,” taking place on Wednesday, April 10, 2024.
The significance of Carisma’s research cannot be overstated. In the realm of oncology, the ability to convert the tumor microenvironment from one that protects the tumor to one that promotes its destruction represents a monumental shift. Traditional therapies often struggle to penetrate these solid tumors due to the protective barriers created by the body’s own cells. By reprogramming macrophages to fight against the tumor, Carisma Therapeutics is at the forefront of creating a new class of immunotherapies that could significantly improve outcomes for patients with hard-to-treat cancers.
This year’s AACR meeting promises to be a fertile ground for discussions on the latest in cancer research, with Carisma Therapeutics poised to make a substantial impact. Industry watchers and stakeholders are keenly awaiting the insights that will emerge from these presentations, hopeful that Carisma’s contributions will mark another step forward in the ongoing battle against cancer. As the company continues to advance its research and development efforts, its presence at AACR 2024 underscores the potential of engineered macrophages to revolutionize cancer treatment paradigms.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.